GSK Posts Strong Q2 as it Moves toward 2022 Demerger

One month after GlaxoSmithKline outlined its plans for the company's future following a planned split between its pharmaceuticals and consumer health businesses, the company posted second quarterly sales of £8.1 (about $11.2) billion.